ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -12 مورد

Chelation therapy for acute arsenic poisoning

Chelation therapy for acute arsenic poisoning
Chelator Dose Administration Adverse effects[1]
Succimer (also known as DMSA)

Use for acute or subacute known or suspected arsenic poisoning without encephalopathy, coma, or severe cardiovascular side effect.

Oral: 10 mg/kg/dose (or 350 mg/m2/dose*) every 8 hours for 5 days, followed by 10 mg/kg/dose (or 350 mg/m2/dose*) every 12 hours for 14 days; maximum: 500 mg/dose.

  • For those with difficulty swallowing capsules (eg, young children), capsules can be opened and contents sprinkled on a small amount of soft food and swallowed immediately.
  • Unit dose is 100 mg capsule. Each dose should be rounded to the nearest 100 mg.

Dermatologic: Rash, pruritus

Gastrointestinal: Nausea, vomiting, diarrhea, abdominal gas and pain

Hematologic: Thrombocytosis, eosinophilia, hemolysis in G6PD deficiency (medium risk)[2]

Hepatic: Transient elevations of hepatic aminotransferases and alkaline phosphatase concentrations

Neurologic: Drowsiness, paresthesias

Respiratory: Rhinorrhea, sore throat

Unithiol (also known as DMPS); not approved by FDA for use in United StatesΔ 5 mg/kg/dose IM:
  • Day 1: Every 6 to 8 hours
  • Day 2: Every 8 to 12 hours
  • Day 3 and thereafter: Every 12 to 24 hours[1]

or

Regimen per product labeling (approved for mercury poisoning)

IV or IM[3]:

  • Day 1: 250 mg every 3 to 4 hours
  • Day 2: 250 mg every 4 to 6 hours
  • Day 3: 250 mg every 6 to 8 hours
  • Day 4: 250 mg every 8 to 12 hours
  • Day 5 and thereafter: 250 mg up to 1 to 3 times daily or transition to oral therapy

Oral[4]: Initial (ie, has not received parenteral treatment): 1.2 to 2.4 g evenly spaced over 24 hours (eg, 100 to 200 mg every 2 hours), reduce dose based on symptoms and laboratory findings.

  • Intravenous, deep IM, or oral.
  • Oral bioavailability is 40% and may be used in less severe poisonings and after initial parenteral treatment once the patient is stabilized.

Dermatologic: Pruritus, toxic epidermal necrolysis

Hematologic: Risk in G6PD deficiency unknown

Gastrointestinal: Nausea

Immunologic: Allergic reactions

Neurologic: Vertigo, weakness

Dimercaprol (also known as British Anti-Lewisite [BAL])

Currently not being manufactured

Use for severe known or suspected arsenic poisoning with encephalopathy, coma, and/or cardiovascular toxicity.

3 to 5 mg/kg IM every 4 to 6 hours.

In severe poisonings, 5 mg/kg IM every 4 hour has been used initially.[1]

The goal is to transition from BAL to an oral chelator. If the patient is clinically improving but not able to take oral medications, tapering the dose is a reasonable option, such as 3 mg/kg for 2 days, then every 6 hours on day 3, followed every 12 hours for up to 10 days.

  • Deep IM.
  • Premedication with diphenhydramine recommended.
  • Rotate injection sites.
  • Maintain alkaline urine pH to protect kidneys.
  • In kidney failure, HD may be required to remove arsenic chelate.

Formulation contains peanut oil; use with caution in peanut allergy

Cardiac: Chest pain, hypertension

Dermatologic: Diaphoresis

Gastrointestinal: Nausea, vomiting, salivation

Hematologic: Hemolysis in G6PD deficiency (high risk)[1,2]

Local: Injection site pain, injection site sterile abscess

Neurologic: Headache

Ophthalmic: Lacrimation

Respiratory: Throat pain, rhinorrhea

Other: Febrile reaction, chelation of essential metals (prolonged course)

Consultation with a medical toxicologist or regional poison center is highly recommended. Regimens shown are those commonly recommended by expert toxicologists. The end point of chelator therapy is a 24-hour urinary arsenic concentration of <50 mcg/L. Refer to UpToDate clinical topics on arsenic exposure and poisoning.

DMPS: 2,3-dimercapto-1-propanesulfuronic acid; DMSA: meso-2,3-dimercaptosuccinic acid; G6PD: glucose 6-phosphate dehydrogenase; IM: intramuscular; IV: intravenous.

* For children <5 years dose should be based on body surface area (ie, mg/m2).

¶ Dosing is based on the use of succimer for the treatment of lead poisoning, which is only approved by the FDA for use in children with a 500 mg maximum dose. Larger doses have been used for lead and arsenic poisoning in adults. Consultation with a medical toxicologist or regional poison center is highly encouraged, especially if considering using larger doses.

Δ Intravenous and oral preparations of DMPS sodium (Brand name: Dimaval) are licensed in some countries of Europe and available for emergency use elsewhere in the world. Limited experience in children.

◊ There are case reports of hemolysis during DMPS treatment in patients with G6PD deficiency.

References:
  1. Munday SW. Arsenic. In: Goldfrank's Toxicologic Emergencies, 11th ed, Nelson LS, Howland MA, Lewin NA, et al (Eds), McGraw-Hill Education 2019.
  2. Drugs that should be avoided – Official list. Italian G6PD Deficiency Association. http://www.g6pd.org/en/G6PDDeficiency/SafeUnsafe/DaEvitare_ISS-it (Accessed September 12, 2024).
  3. Dimaval. Heyl Berlin. https://www.heyl-berlin.de/pharma/poisoning/dimaval/?lang=en (Accessed September 12, 2024).
  4. Dimaval (DMPS) 100 mg hartkapseln. Heyl Berlin. https://www.heyl-berlin.de/pharma/poisoning/dimaval-dmps-100-mg-hartkapseln/?lang=en (Accessed September 12, 2024).

Prepared with additional data from: UpToDate Lexidrug. More information available at https://online.lexi.com/.

Graphic 69443 Version 9.0